What is it about?

Immunotherapy is a new and promising cancer treatment that uses the body's own immune system to fight cancer cells. In Sudan, immunotherapy has shown great promise in the fight against triple-negative breast cancer (TNBC), the type of breast cancer that is difficult to treat with traditional cancer treatments. However, immunotherapy has been shown to be effective in shrinking tumors and extending survival times in patients with TNBC. This is good news for Sudanese women with TNBC. Immunotherapy is a new and promising treatment that has the potential to improve their chances of survival.

Featured Image

Why is it important?

We found that the expression of PD-L1, a predictive marker for immune therapy, was not affected by the patient's age, tumor grade, or stage. This suggests that patients of all ages and with tumors of any grade or stage could be eligible for immune therapy. However, we also found that triple-negative breast cancer (TNBC) was an important factor in predicting how well patients would respond to treatment. This means that patients with TNBC are more likely to benefit from immune therapy than patients with other types of breast cancer.

Perspectives

I was honored to work on this article with esteemed co-authors. We were all motivated to shed light on the struggles of young Sudanese women with breast cancer. These women are more likely to experience the disease at a younger age and suffer more from the side effects of different treatments. We hope that this study will give them hope and encourage more research in this area. We also hope to reach policymakers and stakeholders and share with them the significance of this type of research, which can help identify patients who are more likely to respond to new treatments.

Shahenaz Shaban Mohamed Nour
Sudan University of Science and Technology

Read the Original

This page is a summary of: Expression of Programmed Death Ligand-1 and Correlation with Clinicopathological Features and CD8 Infiltration in Breast Cancer, Sudan Journal of Medical Sciences, June 2023, Knowledge E,
DOI: 10.18502/sjms.v18i2.13602.
You can read the full text:

Read

Contributors

The following have contributed to this page